Trade Genprex, Inc. - GNPX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.1032 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Genprex Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.7084 |
Open* | 2.7184 |
1-Year Change* | 203.8% |
Day's Range* | 2.6984 - 2.9484 |
52 wk Range | 0.19-1.87 |
Average Volume (10 days) | 436.00K |
Average Volume (3 months) | 7.75M |
Market Cap | 12.28M |
P/E Ratio | -100.00K |
Shares Outstanding | 59.43M |
Revenue | N/A |
EPS | -0.61 |
Dividend (Yield %) | N/A |
Beta | -0.45 |
Next Earnings Date | Mar 31, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 2.9284 | 0.2100 | 7.73% | 2.7184 | 2.9584 | 2.6984 |
Mar 27, 2024 | 2.7084 | -0.0400 | -1.46% | 2.7484 | 2.8084 | 2.4984 |
Mar 26, 2024 | 2.7284 | -0.1300 | -4.55% | 2.8584 | 2.8684 | 2.6584 |
Mar 25, 2024 | 2.8984 | -0.3500 | -10.77% | 3.2484 | 3.2584 | 2.8784 |
Mar 22, 2024 | 3.0184 | 0.0600 | 2.03% | 2.9584 | 3.0284 | 2.8984 |
Mar 21, 2024 | 2.9484 | -0.0800 | -2.64% | 3.0284 | 3.0784 | 2.8584 |
Mar 20, 2024 | 2.9684 | -0.2400 | -7.48% | 3.2084 | 3.2584 | 2.8684 |
Mar 19, 2024 | 3.2784 | -0.4800 | -12.77% | 3.7584 | 3.8184 | 3.2084 |
Mar 18, 2024 | 3.9784 | -0.0500 | -1.24% | 4.0284 | 4.1884 | 3.9584 |
Mar 15, 2024 | 4.0484 | -0.0100 | -0.25% | 4.0584 | 4.2084 | 3.9784 |
Mar 14, 2024 | 3.9884 | -0.2200 | -5.23% | 4.2084 | 4.2084 | 3.9384 |
Mar 13, 2024 | 3.9984 | -0.1800 | -4.31% | 4.1784 | 4.2884 | 3.9884 |
Mar 12, 2024 | 4.1984 | -0.3300 | -7.29% | 4.5284 | 4.5284 | 4.0984 |
Mar 11, 2024 | 4.6284 | 0.2600 | 5.95% | 4.3684 | 4.9784 | 4.3684 |
Mar 8, 2024 | 4.3184 | 0.1400 | 3.35% | 4.1784 | 4.3384 | 4.0584 |
Mar 7, 2024 | 4.1284 | -0.0300 | -0.72% | 4.1584 | 4.2984 | 3.9384 |
Mar 6, 2024 | 4.3084 | -0.8100 | -15.83% | 5.1184 | 5.3684 | 4.3084 |
Mar 5, 2024 | 4.0584 | 0.0000 | 0.00% | 4.0584 | 4.1784 | 3.8084 |
Mar 4, 2024 | 4.1684 | -0.2100 | -4.80% | 4.3784 | 4.5884 | 4.1684 |
Mar 1, 2024 | 4.4784 | 0.2400 | 5.66% | 4.2384 | 4.6084 | 4.2184 |
Genprex, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Sunday, March 31, 2024 | ||
Time (UTC) 19:04 | Country US
| Event Q4 2023 Genprex Inc Earnings Release Q4 2023 Genprex Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 22, 2024 | ||
Time (UTC) 19:04 | Country US
| Event Q1 2024 Genprex Inc Earnings Release Q1 2024 Genprex Inc Earnings ReleaseForecast -Previous - |
Wednesday, June 26, 2024 | ||
Time (UTC) 14:00 | Country US
| Event Genprex Inc Annual Shareholders Meeting Genprex Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 23.8307 | 20.6701 | 17.9616 | 10.6827 | 12.3635 |
Selling/General/Admin. Expenses, Total | 12.2951 | 11.6767 | 10.6359 | 8.7026 | 11.3862 |
Research & Development | 11.5101 | 8.97087 | 7.30292 | 1.96701 | 0.97143 |
Depreciation / Amortization | 0.02558 | 0.02253 | 0.02278 | 0.01307 | 0.00589 |
Operating Income | -23.8307 | -20.6701 | -17.9616 | -10.6827 | -12.3635 |
Net Income Before Taxes | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Net Income After Taxes | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Net Income Before Extra. Items | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Net Income | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Income Available to Common Excl. Extra. Items | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Income Available to Common Incl. Extra. Items | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Dilution Adjustment | |||||
Diluted Net Income | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
Diluted Weighted Average Shares | 47.9521 | 47.0973 | 35.5229 | 16.027 | 13.771 |
Diluted EPS Excluding Extraordinary Items | -0.49509 | -0.43877 | -0.5051 | -0.6648 | -0.89843 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -0.49509 | -0.43877 | -0.5051 | -0.6648 | -0.89843 |
Interest Income (Expense), Net Non-Operating | 0.0901 | 0.00513 | 0.01881 | 0.02791 | -0.0088 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | |||
Total Operating Expense | 8.03574 | 9.27125 | 6.82163 | 6.11065 | 5.77039 |
Selling/General/Admin. Expenses, Total | 4.05499 | 3.95708 | 3.49665 | 2.51112 | 2.83692 |
Research & Development | 3.97692 | 5.31015 | 3.3189 | 3.59331 | 2.92693 |
Depreciation / Amortization | 0.00384 | 0.00402 | 0.00608 | 0.00622 | 0.00654 |
Operating Income | -8.03574 | -9.27125 | -6.82163 | -6.11065 | -5.77039 |
Interest Income (Expense), Net Non-Operating | 0.05555 | 0.06847 | 0.0556 | 0.02788 | 0.00574 |
Net Income Before Taxes | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Net Income After Taxes | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Net Income Before Extra. Items | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Net Income | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Income Available to Common Excl. Extra. Items | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Income Available to Common Incl. Extra. Items | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Diluted Net Income | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
Diluted Weighted Average Shares | 51.979 | 49.4716 | 48.0495 | 47.9847 | 47.8934 |
Diluted EPS Excluding Extraordinary Items | -0.15353 | -0.18602 | -0.14081 | -0.12676 | -0.12036 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.15353 | -0.18602 | -0.14081 | -0.12676 | -0.12036 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 21.4732 | 39.1402 | 27.7044 | 2.97664 | 8.84707 |
Cash and Short Term Investments | 20.9541 | 38.6289 | 27.3197 | 2.00249 | 8.60092 |
Cash | 20.9541 | 38.6289 | 27.3197 | 2.00249 | 8.60092 |
Prepaid Expenses | 0.48422 | 0.51135 | 0.38455 | 0.17172 | 0.23685 |
Total Assets | 25.085 | 42.8623 | 31.3672 | 3.53423 | 9.26896 |
Property/Plant/Equipment, Total - Net | 0.02303 | 0.04861 | 0.03944 | 0.04465 | 0.02435 |
Intangibles, Net | 3.56703 | 3.66476 | 3.61267 | 0.4912 | 0.37945 |
Other Long Term Assets, Total | 0.02182 | 0.00869 | 0.01074 | 0.02173 | 0.01809 |
Total Current Liabilities | 2.81029 | 1.5853 | 0.45072 | 0.51068 | 0.38782 |
Accounts Payable | 0.44293 | 0.9732 | 0.19297 | 0.43626 | 0.29507 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.07443 | 0.09275 |
Total Liabilities | 2.81029 | 1.5853 | 0.45072 | 0.51068 | 0.38782 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 22.2747 | 41.277 | 30.9165 | 3.02355 | 8.88114 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.04811 | 0.04787 | 0.04312 | 0.01926 | 0.01524 |
Additional Paid-In Capital | 125.054 | 119.247 | 89.2956 | 43.4837 | 38.6906 |
Retained Earnings (Accumulated Deficit) | -102.828 | -78.0179 | -58.4222 | -40.4795 | -29.8247 |
Total Liabilities & Shareholders’ Equity | 25.085 | 42.8623 | 31.3672 | 3.53423 | 9.26896 |
Total Common Shares Outstanding | 48.106 | 47.8747 | 43.1177 | 19.2638 | 15.2392 |
Total Receivables, Net | 0.03485 | 0 | 0.00013 | 0.00066 | 0.0093 |
Accounts Receivable - Trade, Net | 0.03485 | 0 | 0.00013 | 0.00066 | 0.0093 |
Total Inventory | 0.80178 | ||||
Other Current Liabilities, Total | 2.36736 | 0.6121 | 0.25776 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 12.8571 | 12.3661 | 19.9421 | 21.4732 | 26.3082 |
Cash and Short Term Investments | 11.7113 | 9.95568 | 18.0828 | 20.9541 | 25.5161 |
Cash | 11.7113 | 9.95568 | 18.0828 | 20.9541 | 25.5161 |
Total Receivables, Net | 0 | 0 | 0 | 0.03485 | 0.03485 |
Accounts Receivable - Trade, Net | 0 | 0 | 0 | 0.03485 | 0.03485 |
Total Inventory | |||||
Prepaid Expenses | 1.14576 | 2.41043 | 1.85934 | 0.48422 | 0.75728 |
Total Assets | 16.6436 | 15.9111 | 23.3201 | 25.085 | 29.9458 |
Property/Plant/Equipment, Total - Net | 0.01145 | 0.01518 | 0.01902 | 0.02303 | 0.02911 |
Intangibles, Net | 3.75794 | 3.51268 | 3.33712 | 3.56703 | 3.58671 |
Other Long Term Assets, Total | 0.01715 | 0.01715 | 0.02182 | 0.02182 | 0.02182 |
Total Current Liabilities | 4.33813 | 3.86025 | 4.83522 | 2.81029 | 2.45731 |
Accounts Payable | 1.17919 | 1.49798 | 2.21225 | 0.44293 | 0.68387 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 3.15894 | 2.36227 | 2.62296 | 2.36736 | 1.77344 |
Total Liabilities | 4.33813 | 3.86025 | 4.83522 | 2.81029 | 2.45731 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 12.3055 | 12.0509 | 18.4849 | 22.2747 | 27.4885 |
Common Stock | 0.05943 | 0.05198 | 0.05197 | 0.04811 | 0.04802 |
Additional Paid-In Capital | 140.005 | 132.01 | 130.463 | 125.054 | 122.433 |
Retained Earnings (Accumulated Deficit) | -127.759 | -120.011 | -112.031 | -102.828 | -94.9924 |
Total Liabilities & Shareholders’ Equity | 16.6436 | 15.9111 | 23.3201 | 25.085 | 29.9458 |
Total Common Shares Outstanding | 59.4298 | 51.9791 | 51.9741 | 48.106 | 48.0203 |
Other Equity, Total |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -23.7406 | -19.5956 | -17.9428 | -10.6548 | -12.3723 |
Cash From Operating Activities | -17.779 | -14.2849 | -13.9351 | -6.91872 | -6.84653 |
Cash From Operating Activities | 0.02558 | 0.02253 | 0.02278 | 0.01307 | 0.00589 |
Non-Cash Items | 4.73194 | 4.27821 | 4.24619 | 3.52998 | 5.43538 |
Changes in Working Capital | 1.20414 | 1.00995 | -0.26128 | 0.19299 | 0.08454 |
Cash From Investing Activities | 0.09773 | -0.0838 | -2.33725 | -0.9469 | -0.10332 |
Capital Expenditures | -0.05974 | -0.07244 | -0.12799 | -0.14512 | -0.10332 |
Cash From Financing Activities | 0.00643 | 25.6779 | 41.5895 | 1.26719 | 15.3895 |
Issuance (Retirement) of Stock, Net | 0.00643 | 25.6779 | 41.5895 | 1.26719 | 15.3895 |
Net Change in Cash | -17.6748 | 11.3092 | 25.3172 | -6.59843 | 8.43967 |
Other Investing Cash Flow Items, Total | 0.15747 | -0.01136 | -2.20926 | -0.80178 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.20277 | -23.7406 | -16.9746 | -10.8918 | -5.30982 |
Cash From Operating Activities | -6.93244 | -17.779 | -13.1926 | -8.62165 | -4.0717 |
Cash From Operating Activities | 0.00402 | 0.02558 | 0.0195 | 0.01327 | 0.00673 |
Non-Cash Items | 1.33212 | 4.73194 | 3.18436 | 2.0261 | 1.05744 |
Cash Taxes Paid | |||||
Cash Interest Paid | |||||
Changes in Working Capital | 0.93421 | 1.20414 | 0.57811 | 0.23078 | 0.17395 |
Cash From Investing Activities | -0.01963 | 0.09773 | 0.07805 | 0.0458 | -0.00184 |
Capital Expenditures | -0.01963 | -0.05974 | -0.03974 | -0.02369 | -0.00184 |
Other Investing Cash Flow Items, Total | 0.15747 | 0.11779 | 0.06949 | ||
Cash From Financing Activities | 4.08078 | 0.00643 | 0.00175 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 4.08078 | 0.00643 | 0.00175 | 0 | |
Net Change in Cash | -2.87128 | -17.6748 | -13.1128 | -8.57586 | -4.07354 |
Financing Cash Flow Items | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genprex, Inc. Company profile
About Genprex Inc
Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.
Industry: | Bio Therapeutic Drugs |
1601 Trinity Street, Bldg. B
Suite 3.322
AUSTIN
TEXAS 78712
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com